Targeting EBV-positive B- and T/NK-cell lymphomas

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).
Original languageEnglish
Pages (from-to)2315-2316
Number of pages2
Issue number22
Publication statusPublished - 29 Nov 2018

Bibliographical note

Targeting EBV-positive B- and T/NK-cell lymphomas, Heather M. Long, Blood Nov 2018, 132 (22) 2315-2316; DOI: 10.1182/blood-2018-10-878587


Dive into the research topics of 'Targeting EBV-positive B- and T/NK-cell lymphomas'. Together they form a unique fingerprint.

Cite this